

Supplemental information

**Limbal BCAM expression identifies a proliferative
progenitor population capable of holoclone
formation and corneal differentiation**

Yuzuru Sasamoto, Catherine A.A. Lee, Brian J. Wilson, Florian Buerger, Gabrielle Martin, Ananda Mishra, Shoko Kiritoshi, Johnathan Tran, Gabriel Gonzalez, Friedhelm Hildebrandt, Vickie Y. Jo, Christine G. Lian, George F. Murphy, Bruce R. Ksander, Markus H. Frank, and Natasha Y. Frank

Supplementary Figures




Figure S1. Characterization of BCAM-positive cells in limbus and central cornea. Related to Figure 1.

(A), Representative flow cytometric analyses of BCAM expression in limbal epithelial cells. FSC, forward scatter; SSC, side scatter; A, area; W, width; H, height.

(B), Representative flow cytometric analyses depicting BCAM expression in ABCB5-positive LSCs. FSC, forward scatter; SSC, side scatter; A, area; W, width; H, height.

(C), Bar graphs represent *BCAM* and *KRT12* expression in limbal BCAM-positive and BCAM-negative cells (mean±SD; n= 8; **p < 0.01, ns: not significant). Data were analyzed using a Wilcoxon matched-pairs signed rank test.

(D), Representative flow cytometric analyses of BCAM expression in central corneal epithelial cells. The bar graph depicts the percentage of BCAM-positive cells in the limbus and central cornea (mean±SD; n=11; ns: not significant). Data were analyzed using a paired t-test. FSC, forward scatter; SSC, side scatter; A, area; W, width; H, height.




Figure S2. Isolation and scRNA-seq analyses of ABCB5-positive LSCs from three human donors. Related to Figure 2.

(A) Representative flow cytometric analyses employed for the isolation of ABCB5-positive LSCs. FSC, forward scatter; SSC, side scatter; A, area; W, width; H, height. (B) UMAP of Seurat clustering before batch correction (upper panel) and after batch correction (middle panel) with Harmony. UMAP of Seurat clustering after batch

correction shown for each sample (lower panel). Each color represents an individual patient (n = 3).

(C) List of the top 20 differentially expressed genes enriched in the *BCAM*-high cluster compared to the *BCAM*-low cluster.






Figure S3. Superior proliferation potential of limbal BCAM-positive cells. Related to Figure 3.

(A) Schematic illustration of the holoclone assay (upper panel). Colonies were picked up from the initial colony-forming assay (CFA), dissociated, and seeded onto the new wells. The percentage of holoclones is calculated by multiplying the colony-forming efficiency (CFE) (%) of initial CFA by the percentage of wells containing a holoclone among the seeded wells. Representative macroscopic images of the wells with holoclones generated by limbal BCAM-positive and BCAM-negative cells are shown in the lower panel. Individual colonies are stained with Rhodamine B (pink). CFE; colony-forming efficiency, CFA; colony-forming assay. *Holoclone.

(B), Bar graph represents the relative colony size of BCAM-positive cells in the limbus and central cornea (mean \pm SD; n = 7, *p < 0.05). Data were analyzed using a paired t-test.

(C), Bar graph shows relative cell numbers of cultured BCAM-positive cells in the limbus and central cornea (mean \pm SD; n = 5; ****p < 0.0001). Data were analyzed using a paired t-test.




Figure S4. siRNA-induced BCAM blockade in limbal epithelial cells. Related to Figure 5.

(A) Bar graph depicts *BCAM* mRNA expression in control and *BCAM* siRNA-treated limbal epithelial cells (mean±SD; n = 8; ****p < 0.0001). Data were analyzed using a Dunnett's multiple comparisons test.

(B) Left, representative flow cytometric analysis of BCAM expression in control and *BCAM* siRNA-treated cells limbal epithelial cells. Right, bar graph represents relative percentage of BCAM-positive cells (mean±SD; n = 10; ****p < 0.0001). KD, knockdown. Data were analyzed using a Dunnett's multiple comparisons test.




Figure S5. siRNA-induced p63 blockade attenuates BCAM expression in limbal epithelial cells. Related to Figure 6.

(A) Bar graph depicts *TP63* mRNA expression in control and *TP63* siRNA-treated limbal epithelial cells (mean±SD; n = 8; ****p < 0.001). Data were analyzed using a Dunnett's multiple comparisons test. KD, knockdown.

(B) Left, Western blot analyses of p63 expression in control and *TP63* siRNA-treated limbal epithelial cells. Right, bar graph represents the quantitative analyses of p63 protein expression (mean±SD; n = 3; *p < 0.05, **p < 0.01). Data were analyzed using a Dunnett's multiple comparisons test.

(C), Representative flow cytometric analyses of BCAM expression in control and *TP63* siRNA-treated limbal epithelial cells.

(D) The graph illustrates the position of the *BCAM* promoter sequence used for the luciferase reporter construct visualized using the UCSC genome browser.

Table S1. Donor characteristics for corneas used for single cell RNA-seq analyses and respective figures. Related to Figure 2.

| # | Age | Gender | Smoking | Cause of death | Figures |
|---|-----|--------|---------|---|-----------------------|
| 1 | 28 | Male | - | Acute respiratory distress syndrome caused by silicone injection syndrome | Figures 2, S2, and 4A |
| 2 | 59 | Male | - | Acute Cardiac Event | Figures 2, S2, and 4A |
| 3 | 46 | Male | - | Subarachnoid hemorrhage | Figures 2, S2, and 4A |

Table S2. Donor characteristics for corneas used in validation analyses and respective figures. Related to Figures 1,3,4,5,6

| # | Age | Gender | Smoking | Cause of death | Figures |
|----|-----|--------|---------|--|--|
| 1 | 35 | Male | - | Overdose | Figures 1G, 1H, 1I, 4B and 6A |
| 2 | 62 | Male | - | Lymphoma | Figures 1G, 1H, 1I, 4B and 6A |
| 3 | 58 | Male | - | Probable hypertensive cardiovascular disease | Figures 1G, 1H, 1I, 4B and 6A |
| 4 | 65 | Male | - | End stage renal disease | Figures 6B, S4A and S5A |
| 5 | 74 | Male | + | Cardiac event | Figures 6B, S4A and S5A |
| 6 | 56 | Male | + | Subarachnoid hemorrhage | Figures 5B, 6B, 6C, S4A, S4B, S5A and S5B |
| 7 | 64 | Female | - | Cancer | Figures 5B, 6B, 6C, S4A, S4B, S5A, S5B and S5C |
| 8 | 65 | Male | + | Cancer | Figures 5B, 6B, 6C, S4A, S4B and S5A |
| 9 | 75 | Male | + | Acute cardiac event | Figures 5B, 6B, 6C, S4A, S4B, S5A and 6E |
| 10 | 70 | Male | - | End stage renal disease | Figures 5B, 6B, 6C, S4A, S4B, S5A, S5B and 6E |
| 11 | 50 | Female | - | Acute cardiac event | Figures 4C, 5B, and S4B |
| 12 | 66 | Female | + | Acute cardiac event | Figures 5B, S4A, S4B and 6E |
| 13 | 63 | Female | + | Acute cardiac event | Figures 4C, 5B, 6B, 6C, S4B and S5A |
| 14 | 73 | Male | - | Acute cardiac event | Figures 4C and S4B |
| 15 | 20 | Female | - | Anoxic brain injury | Figures 5C and 6E |
| 16 | 64 | Female | + | Anoxic brain injury | Figure 5C |
| 17 | 75 | Female | + | Cancer | Figures 3D and 5C |

| | | | | | |
|----|----|--------|---|---|--|
| 18 | 70 | Male | + | Acute cardiac event | Figure 5C |
| 19 | 55 | Male | + | Cancer | Figure 5C |
| 20 | 59 | Male | - | Acute cardiac event | Figures 3D, 5A and 5C |
| 21 | 48 | Male | + | Cancer | Figure 5C |
| 22 | 75 | Male | + | Acute cardiac event | Figures 3D and 3E |
| 23 | 58 | Male | + | Congestive Heart Failure | Figures 3D, 3E, 5A and S1D |
| 24 | 55 | Male | + | Cancer | Figures 3D, 3E and 5A |
| 25 | 65 | Male | + | Cancer | Figures 3D, 3E and 5A |
| 26 | 61 | Male | + | Acute cardiac event | Figure 3D |
| 27 | 34 | Male | + | Acute cardiac event | Figure 5A |
| 28 | 59 | Female | + | Acute cardiac event | Figure 5A |
| 29 | 72 | Female | + | Acute cardiac event | Figure 5A |
| 30 | 78 | Female | - | Respiratory | Figures 3A, 3B, 3C, S1D, S3B and S3C |
| 31 | 78 | Female | + | Myocardial infarction | Figure S1A |
| 32 | 19 | Male | - | Anoxic brain injury | Figure S1D |
| 33 | 72 | Female | + | Myocardial infarction | Figure 6E |
| 34 | 74 | Male | + | Acute cardiac event | Figures S4B and 6E |
| 35 | 77 | Female | + | Chronic obstructive pulmonary disease | Figure 3A |
| 36 | 78 | Female | - | Acute cardiac event | Figures 3A and S1C |
| 37 | 55 | Male | + | Sepsis | Figures 3A, 3B and S1C |
| 38 | 79 | Male | + | End stage renal disease | Figure S1C |
| 39 | 71 | Female | - | Acute respiratory failure | Figures 3A and 3B |
| 40 | 64 | Female | - | Cancer | Figures 3A, 3B, S1C and S1D |
| 41 | 75 | Female | - | End stage renal disease | Figures 3A, 3B, 3C, S1C, S1D, S3B and S3C |
| 42 | 70 | Female | + | Respiratory failure | Figures 3A, 3B, 3C, S1C, S1D, S3A, S3B and S3C |
| 43 | 77 | Male | - | Acute cardiac event | Figure S1D |
| 44 | 74 | Female | - | Gastrointestinal bleeding | Figures 3A, 3C, S1D, S3B and S3C |
| 45 | 77 | Female | - | Cerebrovascular accident | Figures 3A, 3B, 3C, S1C, S1D, S3B and S3C |
| 46 | 69 | Female | + | Sepsis | Figures 3A, 3C, S1C, S1D and S3B |
| 47 | 66 | Female | + | Multi-system failure | Figures 3A, 3C, S1D and S3B |
| 48 | 63 | Female | + | Myocardial infarction | Figures 1C, 1D, 1E and 1F |
| 49 | 64 | Female | - | Acute cardiac event | Figures 1C, 1E, 1F and S1B |
| 50 | 74 | Male | + | Cancer | Figures 1C, 1D, 1E and 1F |
| 53 | 72 | Male | + | Acute exacerbation of idiopathic pulmonary fibrosis | Figures 1D and 1E |
| 54 | 74 | Female | - | Intracerebral brain hemorrhage | Figures 1D and 1E |

| | | | | | |
|----|----|------|---|---------|-------------------|
| 55 | 72 | Male | - | Unknown | Figures 1D and 1E |
|----|----|------|---|---------|-------------------|